Giant cell myocarditis

Summary

Giant cell myocarditis (MONDO:0023232) is a disease and 2 clinical trials. Top therapeutic interventions include muromonab-cd3. A subtype of acute myocarditis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	giant cell myocarditis
Mondo ID	MONDO:0023232
ICD-11	507103735
NCIT	C97055
SNOMED CT	60812006
GARD	0006502
NORD	1183
Is cancer (heuristic)	no

Also known as: GCM · giant cell myocarditis · idiopathic giant-cell myocarditis

Disease family

This is a subtype of acute myocarditis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › cardiomyopathy › intrinsic cardiomyopathy › myocarditis › acute myocarditis › giant cell myocarditis

Related subtypes (1): toxic myocarditis

Subtypes (1): idiopathic giant cell myocarditis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004482	PHASE2	COMPLETED	Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
NCT03527342	Not specified	ENROLLING_BY_INVITATION	Sahlgrenska Cardiomyopathy Project

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MUROMONAB-CD3	4	1
CHEMBL15720	0	1